PE20090493A1 - DERIVADOS DE LA 6-CICLOAMINO-3-(PIRIDAZIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA - Google Patents
DERIVADOS DE LA 6-CICLOAMINO-3-(PIRIDAZIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICAInfo
- Publication number
- PE20090493A1 PE20090493A1 PE2008001220A PE2008001220A PE20090493A1 PE 20090493 A1 PE20090493 A1 PE 20090493A1 PE 2008001220 A PE2008001220 A PE 2008001220A PE 2008001220 A PE2008001220 A PE 2008001220A PE 20090493 A1 PE20090493 A1 PE 20090493A1
- Authority
- PE
- Peru
- Prior art keywords
- pyridazin
- pyridazine
- alkylene
- alkyl
- imidazo
- Prior art date
Links
- VTVRXITWWZGKHV-UHFFFAOYSA-N imidazo[1,2-b]pyridazine Chemical compound N1=CC=CC2=NC=CN21 VTVRXITWWZGKHV-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- -1 4-FLUORO-PHENYL Chemical class 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 102000005403 Casein Kinases Human genes 0.000 abstract 1
- 108010031425 Casein Kinases Proteins 0.000 abstract 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract 1
- 239000005018 casein Substances 0.000 abstract 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 abstract 1
- 235000021240 caseins Nutrition 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 206010022437 insomnia Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000026731 phosphorylation Effects 0.000 abstract 1
- 238000006366 phosphorylation reaction Methods 0.000 abstract 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Oncology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
REFERIDA A COMPUESTOS DERIVADOS DE 6-CICLOAMINO-3-(PIRIDAZIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA DE FORMULA (I) DONDE R2 ES ARILO OPCIONALMENTE SUSTITUIDO CON HALOGENO, ALQUILO(C1-C6), ALQUIL(C1-C6)-TIO, -CN, ENTRE OTROS; A ES ALQUILENO(C1-C7) OPCIONALMENTE SUSTITUIDO CON Ra; B ES ALQUILENO(C1-C7) OPCIONALMENTE SUSTITUIDO CON Rb; L ES N OPCIONALMENTE SUSTITUIDO CON UN Rc O Rd, O ES C SUSTITUIDO CON UN Re1 Y UN Rd, ENTRE OTROS, DONDE DOS GRUPOS Ra PUEDEN FORMAR UN ALQUILENO(C1-C6), Ra Y Rb PUEDEN FORMAR UN ENLACE O UN ALQUILENO(C1-C6), Ra Y Rc PUEDEN FORMAR UN ENLACE O UN ALQUILENO(C1-C6), Rb Y Rc PUEDEN FORMAR UN ENLACE O UN ALQUILENO(C1-C6); Rd ES H, ALQUILO(C1-C6), HIDROXI-ALQUILO(C1-C6), FLUOROALQUILO(C1-C6), ENTRE OTROS, Re1 ES -NR4R5, ENTRE OTROS, EN DONDE R4 Y R5 SON CADA UNO H, ALQUILO(C1-C6), CICLOALQUILO(C3-C7), ENTRE OTROS; R7 Y R8 SON CADA UNO H O ALQUILO(C1-C6). SON COMPUESTOS PREFERIDOS: 2-(4-FLUORO-FENIL)-6-PIPERAZIN-1-IL-3-PIRIDAZIN-4-IL-IMIDAZO[1,2-b]PIRIDAZINA, 2-(4-FLUORO-FENIL)-6-((R)-3-METIL-PIPERAZIN-1-IL)-3-PIRIDAZIN-4-IL-IMIDAZO[1,2-b]PIRIDAZINA, 6-(3,3-DIMETIL-PIPERAZIN-1-IL)-2-(4-FLUORO-FENIL)-3-PIRIDAZIN-4-IL-IMIDAZO[1,2-b]PIRIDAZINA, ENTRE OTROS. SE REFIERE TAMBIEN UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA FOSFORILACION DE LA CASEINA POR LAS CASEINA CINASAS 1 EPSILON Y DELTA SIENDO UTILES EN EL TRATAMIENTO DEL INSOMNIO PRIMARIO, SOMNOLENCIA EXCESIVA, TRASTORNOS DE ANSIEDAD
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95071107P | 2007-07-19 | 2007-07-19 | |
| FR0705224A FR2918986B1 (fr) | 2007-07-19 | 2007-07-19 | Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20090493A1 true PE20090493A1 (es) | 2009-05-27 |
Family
ID=39183122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008001220A PE20090493A1 (es) | 2007-07-19 | 2008-07-17 | DERIVADOS DE LA 6-CICLOAMINO-3-(PIRIDAZIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US8455491B2 (es) |
| EP (1) | EP2178879B1 (es) |
| JP (1) | JP5431319B2 (es) |
| KR (1) | KR20100041771A (es) |
| CN (1) | CN101784552A (es) |
| AR (1) | AR069272A1 (es) |
| AU (1) | AU2008300449A1 (es) |
| BR (1) | BRPI0814510A2 (es) |
| CA (1) | CA2693116A1 (es) |
| CL (1) | CL2008002138A1 (es) |
| CO (1) | CO6290690A2 (es) |
| EA (1) | EA016376B1 (es) |
| ES (1) | ES2429765T3 (es) |
| FR (1) | FR2918986B1 (es) |
| MA (1) | MA31616B1 (es) |
| NZ (1) | NZ582683A (es) |
| PA (1) | PA8789901A1 (es) |
| PE (1) | PE20090493A1 (es) |
| TW (1) | TW200914456A (es) |
| UY (1) | UY31236A1 (es) |
| WO (1) | WO2009037394A2 (es) |
| ZA (1) | ZA201001214B (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| WO2009014910A2 (en) | 2007-07-19 | 2009-01-29 | Metabolex, Inc. | N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 receptor for the treatment of diabetes and metabolic disorders |
| US7868001B2 (en) * | 2007-11-02 | 2011-01-11 | Hutchison Medipharma Enterprises Limited | Cytokine inhibitors |
| FR2939134A1 (fr) * | 2008-12-01 | 2010-06-04 | Sanofi Aventis | Derives de 6-cycloamino-3-(1h-pyrrolo°2,3-b!pyridin-4-yl) imidazo°1,2-b!-pyridazine, leur preparation et leur application en therapeutique |
| FR2940285A1 (fr) | 2008-12-19 | 2010-06-25 | Sanofi Aventis | Derives de 6-cycloamino-2-thienyl-3-(pyridin-4-yl)imidazo °1,2-b!-pyridazine et 6-cycloamino-2-furanyl-3- (pyridin-4-yl)imidazo°1,2-b!-pyridazine, leur preparation et leur application en therapeutique |
| FR2940284B1 (fr) * | 2008-12-19 | 2011-02-18 | Sanofi Aventis | Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique |
| WO2011041154A1 (en) | 2009-10-01 | 2011-04-07 | Metabolex, Inc. | Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts |
| WO2011050202A1 (en) | 2009-10-23 | 2011-04-28 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as orexin receptor modulators |
| WO2011050200A1 (en) | 2009-10-23 | 2011-04-28 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as orexin receptor modulators |
| PT2491038T (pt) * | 2009-10-23 | 2016-07-14 | Janssen Pharmaceutica Nv | Octahidropirrolo[3,4-c]pirrolos disubstituídos como modeladores de recetores de orexina |
| CA2778949C (en) | 2009-10-30 | 2018-02-27 | Janssen Pharmaceutica Nv | Imidazo[1,2-b]pyridazine derivatives and their use as pde10 inhibitors |
| AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
| CN109674753A (zh) | 2010-06-23 | 2019-04-26 | 希玛贝治疗股份有限公司 | 固态分散体 |
| US8710231B2 (en) | 2010-08-09 | 2014-04-29 | Pharmadesign, Inc. | Inhibitor of casein kinase 1delta and casein kinase 1E |
| DK2835131T3 (en) | 2010-12-14 | 2017-12-04 | Electrophoretics Ltd | Casein kinase 1 delta inhibitors (CK1 delta) |
| WO2012145581A1 (en) | 2011-04-20 | 2012-10-26 | Janssen Pharmaceutica Nv | Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators |
| AU2012277912B2 (en) | 2011-06-27 | 2017-03-23 | Janssen Pharmaceutica Nv | 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives |
| CA2872216C (en) | 2012-06-26 | 2021-07-20 | Janssen Pharmaceutica Nv | Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl-[1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders |
| CN104411314B (zh) | 2012-07-09 | 2017-10-20 | 詹森药业有限公司 | 磷酸二酯酶10的抑制剂 |
| US9475817B2 (en) | 2012-12-21 | 2016-10-25 | Bristol-Myers Squibb Company | Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors |
| US9556179B2 (en) | 2012-12-21 | 2017-01-31 | Bristol-Myers Squibb Company | Substituted imidazoles as casein kinase 1 D/E inhibitors |
| GB201321734D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| RU2016132574A (ru) * | 2014-01-09 | 2018-02-12 | Интра-Селлулар Терапиз, Инк. | Органические соединения |
| KR102559922B1 (ko) | 2016-03-10 | 2023-07-25 | 얀센 파마슈티카 엔.브이. | 오렉신-2 수용체 길항제를 사용한 우울증의 치료 방법 |
| WO2018026890A1 (en) | 2016-08-03 | 2018-02-08 | Cymabay Therapeutics | Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions |
| AR111295A1 (es) | 2017-03-20 | 2019-06-26 | Forma Therapeutics Inc | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) |
| EP3749667A1 (en) | 2018-02-05 | 2020-12-16 | Alkermes, Inc. | Compounds for the treatment of pain |
| WO2020061255A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| US20200129485A1 (en) | 2018-09-19 | 2020-04-30 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
| TW202112368A (zh) | 2019-06-13 | 2021-04-01 | 荷蘭商法西歐知識產權股份有限公司 | 用於治療有關dux4表現之疾病的抑制劑組合 |
| RS67259B1 (sr) | 2019-09-19 | 2025-10-31 | Novo Nordisk Healthcare Ag | Kompozicije koje aktiviraju piruvat kinazu r (pkr) |
| US20230192699A1 (en) * | 2020-03-27 | 2023-06-22 | Gritscience Biopharmaceuticals Co., Ltd. | Compounds as casein kinase inhibitors |
| CN115335057A (zh) * | 2020-03-27 | 2022-11-11 | 北京原基华毅生物科技有限公司 | 抑制酪蛋白激酶的方法 |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| AU2022367432A1 (en) | 2021-10-14 | 2024-05-02 | Incyte Corporation | Quinoline compounds as inhibitors of kras |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989001333A1 (en) * | 1987-08-07 | 1989-02-23 | The Australian National University | IMIDAZO[1,2-b]PYRIDAZINES |
| ATE322016T1 (de) | 1999-06-08 | 2006-04-15 | Aventis Pharma Inc | Screeningsverfahren zur änderung zirkadiane- rhythmus-eiweisse |
| JP4691506B2 (ja) | 2003-12-11 | 2011-06-01 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | カゼインキナーゼＩεの阻害剤としての置換１Ｈ−ピロロ［３，２−ｂ，３，２−ｃ，及び２，３−ｃ］ピリジン−２−カルボキシアミド及び関連類似物 |
| EP1713784A1 (en) * | 2004-02-12 | 2006-10-25 | Neurogen Corporation | Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands |
| GB0515026D0 (en) * | 2005-07-21 | 2005-08-31 | Novartis Ag | Organic compounds |
| WO2007013673A1 (en) * | 2005-07-29 | 2007-02-01 | Astellas Pharma Inc. | Fused heterocycles as lck inhibitors |
| DE102005042742A1 (de) * | 2005-09-02 | 2007-03-08 | Schering Ag | Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
-
2007
- 2007-07-19 FR FR0705224A patent/FR2918986B1/fr active Active
-
2008
- 2008-07-15 PA PA20088789901A patent/PA8789901A1/es unknown
- 2008-07-17 PE PE2008001220A patent/PE20090493A1/es not_active Application Discontinuation
- 2008-07-17 TW TW097127189A patent/TW200914456A/zh unknown
- 2008-07-17 UY UY31236A patent/UY31236A1/es not_active Application Discontinuation
- 2008-07-18 EA EA201070161A patent/EA016376B1/ru not_active IP Right Cessation
- 2008-07-18 CA CA2693116A patent/CA2693116A1/fr not_active Abandoned
- 2008-07-18 JP JP2010516539A patent/JP5431319B2/ja not_active Expired - Fee Related
- 2008-07-18 WO PCT/FR2008/001057 patent/WO2009037394A2/fr not_active Ceased
- 2008-07-18 BR BRPI0814510-5A2A patent/BRPI0814510A2/pt not_active IP Right Cessation
- 2008-07-18 NZ NZ582683A patent/NZ582683A/en not_active IP Right Cessation
- 2008-07-18 ES ES08831515T patent/ES2429765T3/es active Active
- 2008-07-18 CN CN200880103986A patent/CN101784552A/zh active Pending
- 2008-07-18 CL CL2008002138A patent/CL2008002138A1/es unknown
- 2008-07-18 KR KR1020107001087A patent/KR20100041771A/ko not_active Withdrawn
- 2008-07-18 AR ARP080103097A patent/AR069272A1/es unknown
- 2008-07-18 EP EP08831515.5A patent/EP2178879B1/fr active Active
- 2008-07-18 AU AU2008300449A patent/AU2008300449A1/en not_active Abandoned
-
2010
- 2010-01-11 US US12/685,030 patent/US8455491B2/en not_active Expired - Fee Related
- 2010-01-19 CO CO10004823A patent/CO6290690A2/es not_active Application Discontinuation
- 2010-02-17 MA MA32629A patent/MA31616B1/fr unknown
- 2010-02-19 ZA ZA2010/01214A patent/ZA201001214B/en unknown
-
2013
- 2013-05-06 US US13/887,845 patent/US9108971B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009037394A2 (fr) | 2009-03-26 |
| US20130245023A1 (en) | 2013-09-19 |
| KR20100041771A (ko) | 2010-04-22 |
| CL2008002138A1 (es) | 2009-10-23 |
| CO6290690A2 (es) | 2011-06-20 |
| AR069272A1 (es) | 2010-01-13 |
| EA201070161A1 (ru) | 2010-08-30 |
| EA016376B1 (ru) | 2012-04-30 |
| NZ582683A (en) | 2011-07-29 |
| JP2010533686A (ja) | 2010-10-28 |
| CN101784552A (zh) | 2010-07-21 |
| AU2008300449A1 (en) | 2009-03-26 |
| UY31236A1 (es) | 2009-03-02 |
| US20100152157A1 (en) | 2010-06-17 |
| JP5431319B2 (ja) | 2014-03-05 |
| FR2918986A1 (fr) | 2009-01-23 |
| BRPI0814510A2 (pt) | 2015-02-03 |
| US8455491B2 (en) | 2013-06-04 |
| FR2918986B1 (fr) | 2009-09-04 |
| WO2009037394A3 (fr) | 2009-06-18 |
| CA2693116A1 (fr) | 2009-03-26 |
| MA31616B1 (fr) | 2010-08-02 |
| ES2429765T3 (es) | 2013-11-15 |
| EP2178879A2 (fr) | 2010-04-28 |
| US9108971B2 (en) | 2015-08-18 |
| PA8789901A1 (es) | 2009-02-09 |
| ZA201001214B (en) | 2011-05-25 |
| EP2178879B1 (fr) | 2013-07-03 |
| TW200914456A (en) | 2009-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20090493A1 (es) | DERIVADOS DE LA 6-CICLOAMINO-3-(PIRIDAZIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA | |
| JP6385954B2 (ja) | キナーゼ調節のための化合物および方法、ならびにその適応 | |
| PE20141010A1 (es) | Derivados de piridin-2(1h)-ona utiles como medicamentos para el tratamiento de transtornos mieloproliferativos, rechazo de transplantes, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias | |
| FI3932919T3 (fi) | Jak-inhibiittoriyhdiste ja sen käyttö | |
| JP2018519343A5 (es) | ||
| PE20150218A1 (es) | Nuevos derivados fosfatos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| PE20110572A1 (es) | DERIVADOS DE IMIDAZO[1,2-a]PIRIDINA COMO INHIBIDORES DE MET | |
| PE20190336A1 (es) | Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| PE20090506A1 (es) | DERIVADOS DE IMIDAZO-[1,2-b]-PIRIDAZIN COMO INHIBIDORES DE ALK5 Y/O ALK4 | |
| PE20110545A1 (es) | Compuestos de triazolopiridina como inhibidores de jak | |
| PE20070752A1 (es) | Triazolopiridazinas como moduladores de quinasa | |
| PE20130012A1 (es) | Derivados de pirazol como inhibidores de jak | |
| PE20090370A1 (es) | Derivados de heterociclo fusionado como inhibidores de quinasa | |
| AR053728A1 (es) | Pirimidinas condensadas como agonistas del receptor de acido nicotinico para el tratamiento de dislipidemia y composiciones farmaceuticas que las contienen en combinacion con otros agentes terapeuticos | |
| EA023824B1 (ru) | ПРОИЗВОДНЫЕ 3,4-ДИГИДРОПИРРОЛО[1,2-a]ПИРАЗИН-1-ИЛАМИНА, ПРИГОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕТА-СЕКРЕТАЗЫ (BACE) | |
| PE20090714A1 (es) | Imidazopiridazinas y pirrolo-pirimidinas sustituidas como inhibidores de cinasa de lipido | |
| PE20140390A1 (es) | Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak | |
| PE20151249A1 (es) | Derivados de pirazolopirimidina como inhibidores de jak quinasas | |
| PE20080893A1 (es) | Triazoles biciclicos como moduladores de la proteina cinasa | |
| PE20141974A1 (es) | Compuestos de heterociclilo | |
| PE20120534A1 (es) | PIRIMIDINAS FUSIONADAS COMO INHIBIDORES DE Akt | |
| PE20130611A1 (es) | Triazolopiridinas sustituidas | |
| AR093077A1 (es) | ANTAGONISTAS DE mGlu2/3 PARA EL TRATAMIENTO DE LOS TRASTORNOS AUTISTAS | |
| PE20141351A1 (es) | Triazolopiridinas | |
| PE20110560A1 (es) | NUEVOS DERIVADOS DE TRIAZOLO[4,3-a]PIRIDINA, SU PROCEDIMIENTO DE PREPARACION, SU APLICACION COMO MEDICAMENTOS, COMPOSICIONES FARMACEUTICAS Y NUEVA UTILIZACION PARTICULARMENTE COMO INHIBIDORES DE MET |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |